Clinical Trial

Optimal Pediatric Heart Transplant Immunosuppression With MicroRNAs

Study acronym: OPTIMA
Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to discover circulating microRNAs (associated with drug doses and levels) that can be used to characterize the overall immune state in pediatric heart transplant patients and predict patients that will go on to develop infection and rejection. MicroRNAs (miRs) are small, non-coding RNA molecules that regulate gene expression and serve as molecular biomarkers found in the circulation.
Protocol Amendment History 1 change
notable Sponsor changed: Inova Health Care Services -> Northwestern University 2026-08-12
Trial Details
NCT Number NCT06532890
Lead Sponsor Northwestern University
Conditions Cardiac Failure, Graft Rejection
Enrollment 150 participants
Start Date 2025-02-06
Primary Completion 2029-10-01 (estimated)
Study Completion 2029-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-11